AbCellera receives Health Canada authorization for Phase 1 trial of ABCL575 for atopic dermatitis

AbCellera Biologics Inc.

Health Canada issued No Objection Letter authorizing Clinical Trial Application for ABCL575, an anti-OX40L antibody.
ABCL575 is an Fc-silenced, half-life extended investigational antibody for moderate-to-severe atopic dermatitis.
Phase 1 trial anticipated to start in Q3 2025, evaluating safety and pharmacokinetics in healthy participants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.